Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer

Clinical Biochemistry

Volumn 41, Issue 14-15, 2008, Pages 1140-1149

  Avgeris, Margaritis ^a   Koutalellis, Georgios ^b   Fragoulis, Emmanuel G ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

DDC; L Dopa decarboxylase; LNCaP; PC3; Prostate cancer; PSA; Real time PCR; Tumor biomarkers

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; MESSENGER RNA;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GLEASON SCORE; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DOPA DECARBOXYLASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE;

EID: 55649096438     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.04.026     Document Type: Article

References (85)

1. Issa M.M., and Regan T.S. Medical therapy for benign prostatic hyperplasia-present and future impact. Am J Manag Care 13 Suppl 1 (2007) S4-9
2. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170 2 Pt 1 (2003) 530-547
3. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.L. The development of human benign prostatic hyperplasia with age. J Urol 132 3 (1984) 474-479
4. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
5. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
6. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., and Partin A.W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35 4 (1998) 275-368
7. Yousef G.M., Obiezu C.V., Luo L.Y., Magklara A., Borgono C.A., Kishi T., Memari N., Michael P., Sidiropoulos M., Kurlender L., Economopolou K., Kapadia C., Komatsu N., Petraki C., Elliott M., Scorilas A., Katsaros D., Levesque M.A., and Diamandis E.P. Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem 39 (2005) 11-79
8. Stephan C., Jung K., Diamandis E.P., Rittenhouse H.G., Lein M., and Loening S.A. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59 1 (2002) 2-8
9. Scorilas A., Plebani M., Mazza S., Basso D., Soosaipillai A.R., Katsaros D., Pagano F., and Diamandis E.P. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 54 (2003) 220-229
10. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., deKernion J.B., Ratliff T.L., Kavoussi L.R., Dalkin B.L., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 5 (1994) 1283-1290
11. Scorilas A., Yu H., Soosaipilai A., Gregorakis A., and Diamandis E.P. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clin Chim Acta 292 (2000) 127-138
12. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 1 (1991) 222-226
13. Magklara A., Scorilas A., Catalona W.J., and Diamandis E.P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45 (1999) 1960-1966
14. Lee R., Localio A.R., Armstrong K., Malkowicz S.B., and Schwartz J.S. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 67 4 (2006) 762-768
15. Nam R., Diamandis E.P., Toi A., Trachtenberg J., Magklara A., Scorilas A., Papanastasiou P., Soosaipillai A., Jewett M., and Narod S. Serum human glandular kallikrein (hK2) levels predict the presence of prostate cancer among men with moderately elevated prostate specific-antigen. J Clin Oncol 5 (2000) 1036-1042
16. Partin A.W., Catalona W.J., Finlay J.A., Darte C., Tindall D.J., Young C.Y., Klee G.G., Chan D.W., Rittenhouse H.G., Wolfert R.L., et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 54 5 (1999) 839-845
17. Magklara A., Scorilas A., Stephan C., Kristiansen G.O., Hauptmann S., Jung K., and Diamandis E.P. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56 3 (2000) 527-532
18. Obiezu C.V., Soosaipillai A., Jung K., Stephan C., Scorilas A., Howarth D.H., and Diamandis E.P. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 48 8 (2002) 1232-1240
19. Xi Z., Klokk T.I., Korkmaz K., Kurys P., Elbi C., Risberg B., Danielsen H., Loda M., and Saatcioglu F. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 64 7 (2004) 2365-2370
20. Huggins C., and Hodges C.V. Studies on prostatic cancer: the effectof castration, of estrogen and of androgen injection on serum phosphatasesin metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
21. Yong E.L., Lim J., Qi W., Ong V., and Mifsud A. Molecular basis of androgen receptor diseases. Ann Med 32 1 (2000) 15-22
22. Brinkmann A.O., Blok L.J., de Ruiter P.E., Doesburg P., Steketee K., Berrevoets C.A., and Trapman J. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 69 1-6 (1999) 307-313
23. Shang Y., Myers M., and Brown M. Formation of the androgen receptor transcription complex. Mol Cell 9 3 (2002) 601-610
24. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 88 12 Suppl (2000) 3009-3014
25. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 1 (2001) 34-45
26. Eder I.E., Culig Z., Putz T., Nessler-Menardi C., Bartsch G., and Klocker H. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 40 3 (2001) 241-251
27. Bharaj B., Scorilas A., Diamandis E.P., Giai M., Levesque M.A., Sutherland D.J., and Hoffman B.R. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. Breast Cancer Res Treat 61 (2000) 111-119
28. Mousses S., Wagner U., Chen Y., Kim J.W., Bubendorf L., Bittner M., Pretlow T., Elkahloun A.G., Trepel J.B., and Kallioniemi O.P. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20 46 (2001) 6718-6723
29. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., and Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9 4 (1995) 401-406
30. Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., Trapman J., Cleutjens K., Noordzij A., Visakorpi T., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57 2 (1997) 314-319
31. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., and Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61 9 (2001) 3550-3555
32. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., and Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173 2 (1990) 534-540
33. Taplin M.E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B., and Balk S.P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59 11 (1999) 2511-2515
34. Wallen M.J., Linja M., Kaartinen K., Schleutker J., and Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 189 4 (1999) 559-563
35. Marcelli M., Ittmann M., Mariani S., Sutherland R., Nigam R., Murthy L., Zhao Y., DiConcini D., Puxeddu E., Esen A., et al. Androgen receptor mutations in prostate cancer. Cancer Res 60 4 (2000) 944-949
36. Tilley W.D., Buchanan G., Hickey T.E., and Bentel J.M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2 2 (1996) 277-285
37. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., and Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 20 (1994) 5474-5478
38. Ueda T., Bruchovsky N., and Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277 9 (2002) 7076-7085
39. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., and Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96 10 (1999) 5458-5463
40. Yeh S., and Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A 93 11 (1996) 5517-5521
41. Voeller H.J., Truica C.I., and Gelmann E.P. Beta-catenin mutations in human prostate cancer. Cancer Res 58 12 (1998) 2520-2523
42. Truica C.I., Byers S., and Gelmann E.P. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60 17 (2000) 4709-4713
43. Christenson J.G., Dairman W., and Udenfriend S. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic l-amino acid decarboxylase-serotonin-dopamine-norepinephrine). Proc Natl Acad Sci U S A 69 2 (1972) 343-347
44. Poulikakos P., Vassilacopoulou D., and Fragoulis E.G. L-DOPA decarboxylase association with membranes in mouse brain. Neurochem Res 26 5 (2001) 479-485
45. Mappouras D.G., Stiakakis J., and Fragoulis E.G. Purification and characterization of L-dopa decarboxylase from human kidney. Mol Cell Biochem 94 2 (1990) 147-156
46. Ichinose H., Kojima K., Togari A., Kato Y., Parvez S., Parvez H., and Nagatsu T. Simple purification of aromatic l-amino acid decarboxylase from human pheochromocytoma using high-performance liquid chromatography. Anal Biochem 150 2 (1985) 408-414
47. Dominici P., Tancini B., Barra D., and Voltattorni C.B. Purification and characterization of rat-liver 3,4-dihydroxyphenylalanine decarboxylase. Eur J Biochem 169 1 (1987) 209-213
48. Shirota K., and Fujisawa H. Purification and characterization of aromatic l-amino acid decarboxylase from rat kidney and monoclonal antibody to the enzyme. J Neurochem 51 2 (1988) 426-434
49. Fragoulis E.G., and Sekeris C.E. Purification and characteristics of DOPA-decarboxylase from the integument of Calliphora vicina larve. Arch Biochem Biophys 168 1 (1975) 15-25
50. Mappouras D.G., and Fragoulis E.G. L-dopa decarboxylase in Ceratitis capitata white puparia and human: a comparative study. Comp Biochem Physiol B 97 2 (1990) 301-306
51. Bossinakou K.S., and Fragoulis E.G. Purification and characterisation of L-DOPA decarboxylase from pharate pupae of Ceratitis capitata. A comparison with the enzyme purified from the white prepupae. Comp Biochem Physiol B Biochem Mol Biol 113 2 (1996) 213-220
52. Lovenberg W., Weissbach H., and Udenfriend S. Aromatic l-amino acid decarboxylase. J Biol Chem 237 (1962) 89-93
53. Boomsma F., Ausema L., Hakvoort-Cammel F.G., Oosterom R., Man in't Veld A.J., Krenning E.P., Hahlen K., and Schalekamp M.A. Combined measurements of plasma aromatic l-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma. Eur J Cancer Clin Oncol 25 7 (1989) 1045-1052
54. Gilbert J., Haber M., Bordow S.B., Marshall G.M., and Norris M.D. Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. Am J Pathol 155 1 (1999) 17-21
55. Bozzi F., Luksch R., Collini P., Gambirasio F., Barzano E., Polastri D., Podda M., Brando B., and Fossati-Bellani F. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagn Mol Pathol 13 3 (2004) 135-143
56. Jensen S.M., Gazdar A.F., Cuttitta F., Russell E.K., and Linnoila R.I. A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. Cancer Res 50 18 (1990) 6068-6074
57. Sakakura C., Takemura M., Hagiwara A., Shimomura K., Miyagawa K., Nakashima S., Yoshikawa T., Takagi T., Kin S., Nakase Y., et al. Overexpression of dopa decarboxylase in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT-PCR. Br J Cancer 90 3 (2004) 665-671
58. Wafa L.A., Cheng H., Rao M.A., Nelson C.C., Cox M., Hirst M., Sadowski I., and Rennie P.S. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J 375 Pt 2 (2003) 373-383
59. Shao C., Wang Y., Yue H.H., Zhang Y.T., Shi C.H., Liu F., Bao T.Y., Yang Z.Y., Yuan J.L., and Shao G.X. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. J Androl 28 6 (2007) 804-812
60. Margiotti K., Wafa L.A., Cheng H., Novelli G., Nelson C.C., and Rennie P.S. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Mol Cancer 6 (2007) 38
61. Cohen R.J., Glezerson G., and Haffejee Z. Neuro-endocrine cells-a new prognostic parameter in prostate cancer. Br J Urol 68 3 (1991) 258-262
62. Theodorescu D., Broder S.R., Boyd J.C., Mills S.E., and Frierson Jr. H.F. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80 11 (1997) 2109-2119
63. Weinstein M.H., Partin A.W., Veltri R.W., and Epstein J.I. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 27 7 (1996) 683-687
64. Huang J., Yao J.L., Zhang L., Bourne P.A., Quinn A.M., di Sant'Agnese P.A., and Reeder J.E. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 166 6 (2005) 1807-1815
65. Hu Y., Ippolito J.E., Garabedian E.M., Humphrey P.A., and Gordon J.I. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 277 46 (2002) 44462-44474
66. Ippolito J.E., Xu J., Jain S., Moulder K., Mennerick S., Crowley J.R., Townsend R.R., and Gordon J.I. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci U S A 102 28 (2005) 9901-9906
67. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) Method. Methods 25 4 (2001) 402-408
68. Wafa L.A., Palmer J., Fazli L., Hurtado-Coll A., Bell R.H., Nelson C.C., Gleave M.E., Cox M.E., and Rennie P.S. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 38 1 (2007) 161-170
69. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22 (1994) 3181-3186
70. Kazemi-Esfarjani P., Trifiro M.A., and Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 4 (1995) 523-527
71. Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur Urol 35 (1999) 362-369
72. Irvine R.A., Ma H., Yu M.C., Ross R.K., Stallcup M.R., and Coetzee G.A. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9 (2000) 267-274
73. Irvine R.A., Yu M.C., Ross R.K., and Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55 (1995) 1937-1940
74. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94 (1997) 3320-3323
75. Hsing A.W., Gao Y.T., Wu G., Wang X., Deng J., Chen Y.L., et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 60 (2000) 5111-5116
76. Stanford J.L., Just J.J., Gibbs M., Wicklund K.G., Neal C.L., Blumenstein B.A., and Ostrander E.A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57 (1997) 1194-1198
77. Bratt O., Borg A., Kristoffersson U., Lundgren R., Zhang Q.X., and Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 81 (1999) 672-676
78. Hardy D.O., Scher H.I., Bogenreider T., Sabbatini P., Zhang Z.F., Nanus D.M., and Catterall J.F. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 81 (1996) 4400-4405
79. Bharaj B., Scorilas A., Diamandis E.P., Giai M., Levesque M.A., Sutherland D.J., and Hoffman B.R. A prevalent polymorphism in the proximal androgen response element of the prostate specific antigen gene and its implications for breast cancer patients. Breast Cancer Res Tr 61 (2000) 111-119
80. Edwards A., Hammond H.A., Jin L., Caskey C.T., and Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12 (1992) 241-253
81. Chang B.L., Zheng S.L., Hawkins G.A., Isaacs S.D., Wiley K.E., Turner A., et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet 110 (2002) 122-129
82. Craig S.P., Thai A.L., Weber M., and Craig I.W. Localisation of the gene for human aromatic l-amino acid decarboxylase (DDC) to chromosome 7p13Äp11 by in situ hybridisation. Cytogenet Cell Genet 61 (1992) 114-116
83. O'Malley K.L., Harmon S., Moffat M., Uhland-Smith A., and Wong S. The human aromatic l-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. J Neurochem 65 (1995) 2409-2416
84. Chang Y.T., Mues G., and Hyland K. Alternative splicing in the coding region of human aromatic l-amino acid decarboxylase mRNA. Neurosci Lett 202 (1996) 157-160
85. Vassilacopoulou D., Sideris D.C., Vassiliou A.G., and Fragoulis E.G. Identification and characterization of a novel form of the human L-dopa decarboxylase mRNA. Neurochem Res 29 (2004) 1817-1823